ReviewMagyar onkologia2025
[Germline mutations define the prognosis and therapy of pheochromocytomas and paragangliomas].
Review in Magyar onkologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pheochromocytomas and paragangliomas are rare neuroendocrine tumors, where the genetic background is of particular importance in terms of the diagnosis, follow-up, treatment and prognosis of the disease. Although the prognosis in benign cases is encouraging, in the case of malignant disease the mortality rates are dramatically worse due to the high tumor burden and possible cardiovascular complications caused by catecholamine oversecretion. In recent years, significant progress has been made both in the functional imaging of the disease and in the therapy of malignant diseases, which in many cases are also related to the underlying genetic background. The aim of our brief summary is to place the diverse genetic background and tumor biology of the disease in the context of diagnostics and therapy, thus highlighting the importance of our understanding of the disease at the individual patient level.
Indexed as
Identifiers
40117485PMC11929578What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.